View by Specialty

Trending

PC0125Qi_Graphic_01_WEB
January 10, 2025
3 min read
Save

Drinking coffee in the morning reduces the risk for death

Autoimmune/Cholestatic/Biliary Diseases News

SPONSORED CONTENT
January 08, 2025
1 min read
Save
Cour Pharmaceuticals snags orphan drug designation for CNP-104 for the treatment of PBC

Cour Pharmaceuticals snags orphan drug designation for CNP-104 for the treatment of PBC

The FDA has granted Cour Pharmaceuticals orphan drug designation for CNP-104, a biodegradable nanoparticle in development for the treatment of primary biliary cholangitis, the company announced in a press release.

SPONSORED CONTENT
December 31, 2024
6 min read
Save

Ocaliva down but not out: A timeline of FDA troubles for a once-promising PBC contender

Ocaliva down but not out: A timeline of FDA troubles for a once-promising PBC contender

Eight years ago, Ocaliva was a prospective lifesaver for patients with primary biliary cholangitis who failed to adequately respond to first-line ursodeoxycholic acid. However, the once-promising drug now finds itself struggling to deliver.

SPONSORED CONTENT
December 12, 2024
2 min read
Save

FDA: Ocaliva still linked to ‘serious liver injury’ in PBC, even without cirrhosis

FDA: Ocaliva still linked to ‘serious liver injury’ in PBC, even without cirrhosis

The FDA has issued a safety alert warning that obeticholic acid carries an increased risk for “serious liver injury” among patients with primary biliary cholangitis, even those without advanced cirrhosis.

Trending

PC0125Qi_Graphic_01_WEB
January 10, 2025
3 min read
Save

Drinking coffee in the morning reduces the risk for death

SPONSORED CONTENT
November 27, 2024
1 min read
Save

Researchers seek to improve the 'diagnostic odyssey' of infant biliary atresia evaluations

SAN DIEGO — A new ultrasound approach may help more quickly and less invasively identify infants with biliary atresia, according to research presented at The Liver Meeting.

SPONSORED CONTENT
November 26, 2024
2 min read
Save

Patients with PBC who failed with obeticholic acid may still achieve ‘some benefit’

Patients with PBC who failed with obeticholic acid may still achieve ‘some benefit’

SAN DIEGO — Patients with primary biliary cholangitis who were incomplete responders to obeticholic acid may still demonstrate improvement in inflammatory markers and fibrosis scores, according to research presented at The Liver Meeting.

SPONSORED CONTENT
November 25, 2024
2 min read
Save

Livdelzi reduces cholestatic, liver injury markers in patients with PBC and cirrhosis

Livdelzi reduces cholestatic, liver injury markers in patients with PBC and cirrhosis

SAN DIEGO — Livdelzi appeared safe and well-tolerated and reduced markers of cholestasis and liver injury in patients with primary biliary cholangitis, including those with compensated cirrhosis, according to a presenter.

SPONSORED CONTENT
November 15, 2024
2 min read
Save

Mycophenolate ‘comparable, if not better’ than azathioprine for autoimmune hepatitis

Mycophenolate ‘comparable, if not better’ than azathioprine for autoimmune hepatitis

PHILADELPHIA — Mycophenolate mofetil appeared to be more efficacious and tolerable than azathioprine in patients with autoimmune hepatitis, especially among those aged older than 50 years and with lower IgG levels, according to a presenter.

SPONSORED CONTENT
November 14, 2024
2 min read
Save

Pharmacotherapy for alcohol use disorder ‘underutilized’ in at-risk populations

Pharmacotherapy for alcohol use disorder ‘underutilized’ in at-risk populations

PHILADELPHIA — Pharmacologic therapy for alcohol use disorder may be an “underutilized treatment modality,” especially in patients with related liver disease, according to research presented at the ACG Annual Scientific Meeting.

SPONSORED CONTENT
November 14, 2024
2 min watch
Save

VIDEO: ‘Encouraging’ safety data on Livdelzi in primary biliary cholangitis, cirrhosis

VIDEO: ‘Encouraging’ safety data on Livdelzi in primary biliary cholangitis, cirrhosis

PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, highlights a presentation at the ACG Annual Scientific Meeting investigating the use of Livdelzi in patients with primary biliary cholangitis and cirrhosis.

SPONSORED CONTENT
November 13, 2024
2 min watch
Save

VIDEO: Treating autoimmune hepatitis with mycophenolate ‘still a cautionary tale’

VIDEO: Treating autoimmune hepatitis with mycophenolate ‘still a cautionary tale’

PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, speaks with Healio about findings from a systemic review and meta-analysis on the efficacy of mycophenolate mofetil compared with azathioprine for autoimmune hepatitis.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails